Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083539 | 1.00 | CYP11B1 (0.59) | CYP11B1CYP11B2TAAR1CYP3A4LDHA | |
| Hydrochloric Acid SCHEMBL5010818 | 0.98 | CYP11B1 (0.57) | CYP11B1CYP11B2TAAR1CYP3A4LDHA | |
| SCHEMBL2414535 | 0.85 | CYP11B1 (0.56) | CYP11B1CYP11B2TAAR1CYP3A4LOXL2 | |
| SCHEMBL351473 | 0.83 | LOXL2 (0.46) | CYP11B1CYP11B2TAAR1LOXL2CYP2A6 | |
| SCHEMBL14355099 | 0.82 | CYP11B1 (0.57) | CYP11B1CYP11B2CYP3A4LOXL2CYP2A6 | |
| SCHEMBL23929936 | 0.82 | LOXL2 (0.64) | CYP11B1CYP11B2CYP3A4LOXL2CYP2A6 | |
| SCHEMBL30175280 | 0.82 | LOXL2 (0.64) | CYP11B1CYP11B2CYP3A4LOXL2CYP2A6 | |
| SCHEMBL30175278 | 0.82 | LOXL2 (0.64) | CYP11B1CYP11B2CYP3A4LOXL2CYP2A6 | |
| SCHEMBL6673316 | 0.81 | AURKA (0.54) | CYP11B1CYP11B2TAAR1CYP3A4NPC1 | |
| Hydrochloric Acid SCHEMBL31716140 | 0.81 | CYP11B1 (0.54) | CYP11B1CYP11B2CYP3A4LOXL2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-11-21 | — | — | US | disclosed |
| CN-117940427-A | Substituted pyrazolo [1,5-a ] pyrimidine-7-amine compounds as CDK inhibitors and therapeutic uses thereof | 卡里克治疗有限公司 | 2024-04-26 | — | — | CN | disclosed |
| EP-4355426-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023158221-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | 주식회사 카나프테라퓨틱스 | 2023-08-24 | — | — | WO | disclosed |
| WO-2022263604-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | Carrick Therapeutics Limited (IE) | 2022-12-22 | — | — | WO | disclosed |
| EP-2810944-A1 | HETEROCYCLIC COMPOUND HAVING ANTI-HIV ACTIVITY | Toyama Chemical Co., Ltd. (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-2406263-B1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NAT RECH SCIENT (FR) | 2013-09-25 | — | — | EP | disclosed |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-07-19 | — | — | US | disclosed |
| EP-2406263-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Centre National de la Recherche Scientifique (C.N.R.S.) (FR) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103486-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103486-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010103473-A1 | METHOD OF TREATMENT OF POLYCYSTIC DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA | CHU DE BREST (FR) | 2010-09-16 | — | — | WO | disclosed |
| US-20060287378-A1 | Novel pyrroles and imidazoles | WARNER-LAMBERT COMPANY LLC | 2006-12-21 | — | — | US | disclosed |
| US-20050239857-A1 | Novel imidazoles | BOLTON GARY L | 2005-10-27 | — | — | US | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287378-A1 | Novel pyrroles and imidazoles | PPIP5K2, PPIE, PPOX | CYP11B1 331/4885CYP11B2 237/4885TAAR1 2250/4885 |
| US-20120184557-A1 | PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | AOC3, CBR3, RTN3 | CYP11B1 1567/4885CYP11B2 1407/4885TAAR1 261/4885 |
| US-20050239857-A1 | Novel imidazoles | HMGCR, HMGB2, HMGB3 | CYP11B1 5/4885CYP11B2 4/4885TAAR1 3974/4885 |
| US-20240383900-A1 | SUBSTITUTED PYRAZOLO [1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE | CDK3, CDK1, CDK2 | CYP11B1 3042/4885CYP11B2 2911/4885TAAR1 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.